Teresa F. Pais holds her PhD in Biomedical Sciences from University of Porto. She has worked in innate immune responses in the context of both infection and neurodegeneration. Currently, she is a researcher at Instituto de Medicina Molecular where she investigates inflammatory processes in the brain.
Patients who undergo splenectomy, or surgery to remove the spleen, increase their risk of pulmonary hypertension (PH), myocardial infarction and stroke. That’s the conclusion of a study, “Risk of cardiovascular events and ... Read more
Treatment with aloperine, a traditional Eastern herbal medicine, reduces markers of oxidative stress and improves heart parameters in a pulmonary hypertension (PH) animal model. The results were reported in a study ... Read more
The rapid growth of smooth muscle cells in pulmonary arteries causes vasoconstriction and pulmonary arterial hypertension (PAH). Now, researchers found that the same drugs that inhibit cancer cell growth ... Read more
Treprostinil improves exercise performance and lowers blood pressure in sickle-cell disease (SCD) patients with pulmonary hypertension (PH), a study shows. The therapy was also well tolerated by the patients, ... Read more
Children born to women with late-stage gestational diabetes — caused by a pregnancy-related, transient increase in blood sugar levels (hyperglycemia) — or to women who are overweight or obese are ... Read more
A French research team was able to demonstrate nebivolol’s beneficial effects in treating pulmonary arterial hypertension (PAH), suggesting that new clinical studies should be conducted to further test the drug. The study entitled: ... Read more
Earlier in the week, Pulmonary Hypertension News reported on how the drug Bosentan improved Pulmonary Hypertension Secondary to IPF in an individual case study. In a related story, medical ... Read more